Amneal Pharmaceuticals, Inc. (AMRX) stock
AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3062% above fair value
$21.23−0.15 (-0.70%)
Close on Nov 16, 2026Market cap $6.78BP/E 43.3Yield –
Amneal Pharmaceuticals EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Amneal Pharmaceuticals's EV/EBITDA was 21.0× on Nov 11, 2026, against 17.8× a year earlier. Over the last 5 years it ranged from 12.3× to 68.1×, with a median of 19.8×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 21.0× | +3.1 |
| 2025 | Dec 31, 2025 | 17.9× | −6.8 |
| 2024 | Dec 31, 2024 | 24.7× | +10.4 |
| 2023 | Dec 29, 2023 | 14.4× | −9.0 |
| 2022 | Jul 29, 2022 | 23.4× | +3.8 |
| 2021 | Dec 31, 2021 | 19.6× | −47.7 |
| 2020 | Dec 31, 2020 | 67.3× | −38.9 |
| 2019 | Jan 31, 2019 | 106.2× | −2.2 |
| 2018 | Dec 31, 2018 | 108.4× | – |
See a number that looks wrong?